The skeletal effects of the tyrosine kinase inhibitor nilotinib.
O'Sullivan S, Lin JM, Watson M, Callon K, Tong PC, Naot D, Horne A, Aati O, Porteous F, Gamble G, Cornish J, Browett P, Grey A.
O'Sullivan S, et al. Among authors: porteous f.
Bone. 2011 Aug;49(2):281-9. doi: 10.1016/j.bone.2011.04.014. Epub 2011 Apr 29.
Bone. 2011.
PMID: 21550432
Clinical Trial.